Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-398 + Cyclophosphamide in Pediatric Solid Tumors
NCT02013336Phase 1Recruiting
- Sponsor
- South Plains Oncology Consortium
- Start
- Dec 2013
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan liposome injection in solid tumor, Ewing sarcoma, rhabdomyosarcoma (RMS) and 2 more, sponsored by South Plains Oncology Consortium. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Dec 2013; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
solid tumorEwing sarcomarhabdomyosarcoma (RMS)neuroblastomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT02013336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013336.